B-cell prolymphocytic leukemia epidemiology and demographics: Difference between revisions
Carlos Lopez (talk | contribs) No edit summary |
Carlos Lopez (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
{{CMG}};{{CLG}} | {{CMG}};{{CLG}} | ||
== Overview == | == Overview == | ||
The incidence is 1% of lymphocytic leukemias. B-cell prolymphocytic leukemia affects men and women equally. | |||
==Epidemiology and demographics== | ==Epidemiology and demographics== | ||
| Line 11: | Line 12: | ||
===Incidence=== | ===Incidence=== | ||
* B-cell prolymphocytic leukemia incidence is | * B-cell prolymphocytic leukemia incidence is 1% of lymphocytic leukemias | ||
===Gender=== | ===Gender=== | ||
Revision as of 13:58, 7 October 2015
|
B-cell prolymphocytic leukemia |
|
Differentiating B-cell prolymphocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
B-cell prolymphocytic leukemia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of B-cell prolymphocytic leukemia epidemiology and demographics |
|
FDA on B-cell prolymphocytic leukemia epidemiology and demographics |
|
CDC on B-cell prolymphocytic leukemia epidemiology and demographics |
|
B-cell prolymphocytic leukemia epidemiology and demographics in the news |
|
Blogs on B-cell prolymphocytic leukemia epidemiology and demographics |
|
Directions to Hospitals Treating B-cell prolymphocytic leukemia |
|
Risk calculators and risk factors for B-cell prolymphocytic leukemia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Carlos A Lopez, M.D. [2]
Overview
The incidence is 1% of lymphocytic leukemias. B-cell prolymphocytic leukemia affects men and women equally.
Epidemiology and demographics
Age
- B-cell prolymphocytic leukemia is around 65-69 years median age[1]
Incidence
- B-cell prolymphocytic leukemia incidence is 1% of lymphocytic leukemias
Gender
- There is no male or female predominance in B-cell prolymphocytic leukemia
Survival
- There is 30-50 months median survival for this disease.